Headquartered in Hungary, Gedeon Richter Plc. is a Pan-European innovation-driven specialty pharmaceutical company involved in pharmaceutical manufacturing, research and development, sales and marketing.
The company produces about two hundred pharmaceutical products in more than 400 presentations. The product portfolio covers almost all important therapeutic areas, including gynaecology, central nervous system and cardiovascular. Furthermore, the biotechnological facilities will help the firm expand its product portfolio with products offering high added value.
Gedeon Richter has the largest R&D unit in Central Eastern Europe. Original research focuses on central nervous system disorders, with main clinical targets being schizophrenia, anxiety, chronic pain and depression, as well as the treatment of benign gynaecological conditions. With its widely acknowledged steroid chemistry expertise and comprehensive female healthcare product range, Richter is a significant player in the gynecological field worldwide.
Our company has been making products for the protection of women's reproductive health since its establishment in 1901. Over the past decades our range of gynaecological products has expanded considerably, with the addition of modern contraceptive
and emergency contraceptive pills, a variety of hormone replacement therapy (HRT) treatments, including two types of skin patch, as well as disinfectant and myoma products and other preparations for gynaecological use.
Since the early 1970s, investigators have studied the use of Levonorgestrel, an active ingredient formerly used in oral contraceptive pills, given alone for Emergency Contraception. Since that time, a series of clinical trials completed in Eastern Europe with levonorgestrel manufactured by Gedeon Richter Plc. showed the efficacy and safety of levonogestrel as alone for postcoital contraception. Levonorgestrel 0.75 mg tablet was first approved in Hungary in 1979 under the trade name of Postinor. The preparation was marketed largely in Eastern and Central Europe and the former Soviet Union and later on at the beginning of the early 1990s produced for Western Europe , USA and rest of the world.
We offer a broad range of contraceptive options to assist women to shape their lives according to their wishes. When it comes to the choice of contraceptive methods, reliability, safety, ease of use and convenience all play a major role. Step by step we have built up a product portfolio, which contains a number of second, third and fourth generation oral contraceptives and emergency contraceptives providing a wide range for the female population to choose products which fit most with their personal needs. By now Gedeon Richter Plc. is a leading oral contraceptive producer in global terms.
Oral contraceptives also have a number of important preventive properties. For example they regulate the menstrual cycle, contribute to the general well-being that accompany the mid-term and pre-menstrual stages, offer protection against iron-deficiency anaemia, pelvic inflammatory disease and ovarian cancer, as well as benign uterine and breast tumours. Naturally, hormonal contraception, just like the use of any other medicine, is not entirely risk-free. However, the benefit of protection from an unwanted pregnancy and its complications far outweighs the possible risk of taking oral hormonal contraceptives.
The company’s product portfolio is now being expanded by an effective product for the pre-operative treatment of myomas that can help improve the quality of life of women suffering from this disease.
Uterine fibroids affect approximately up to 40% of women.The most frequent type of myoma is the one located in the wall of the uterus. Myomas can grow towards the endometrial cavity, within the wall of the uterus, or outwards to the abdominal cavity. They come in a great variety of sizes, ranging from a few millimetres up to a size that can fill most of the abdominal cavity.Their pathogenesis is still unclear.
The appearance and severity of complaints are related to the location and size of the myomas.
The characteristic symptoms of myomas include abnormal menstrual cycles, excessive uterine bleeding, anaemia cramps, abdominal pain, frequent urination or incontinence, infertility and pregnancy complications.In the case of asymptomatic myomas, regular gynaecological and ultrasonography tests may be sufficient, but if the condition causes symptoms, either surgical or medical therapy is required.
From the year of 2012 there is an oral pre-operative pharmacology intervention available.
The new innovative oral drug exerts modulator effect on the receptor of one of the sex hormones in the body, progesterone. The product effectively stops bleeding, reduces anemia and decreases the size of the myoma which contribute to the improved quality of life of patients.
With this new oral pre-operative treatment, the patient gains time so she can be better informed by the gynecologist of the consequences and possibilities of different approaches to myoma’s treatment.
Vaginal fungal infections have recently begun to assume endemic proportions. Some 75% of women will be infected at least once in their life, and in 5% of cases the infection will be recurring, in other words it will return four or more times a year, severely detracting from women's quality of life. Our widely available modern systematic and topical antifungal agents offer an effective treatment for acute and chronic recurring vaginal fungal infections.
Demographic data shows that life expectancies today are considerably higher than in the past, and as a consequence, more women than ever before live through the ‘change of life’ referring to the menopausal transition (climacteric). The climacteric is not a disease, but a physiological process – a fact of life for all women when several symptoms occur such as hot flashes, nocturnal perspiration, insomnia and mood swings which may interfere with the daily activity. Hormone replacement therapy is given to provide relief of vasomotor symptoms, to avoid the irregularity of menstrual cycles, to preserve bone density and consequently to improve quality of life.
This page has been prepared to provide information to patients. The data presented should not be used to reach a diagnosis. In case you exhibit the symptoms above, consult your doctor immediately! In order to learn about potential risks and side effects, please read the patient information leaflet or consult your doctor, pharmacist.